Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tedizolid Phosphate Formulations in Healthy Adults
NCT06609161Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tedizolid in acute bacterial skin and skin structure infections (ABSSSI) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity, Area Under the Concentration-Time Curve from Time 0 to Last Quantifiable Concentration and 1 more. Started Jul 2024; status: completed.
02
Drugs
tedizolid
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT06609161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609161.